Apimeds Pharmaceuticals Us, INC 8-K filings

Apimeds Pharmaceuticals US, Inc. has appointed Dr. Christopher Kim as Chief Scientific Officer to lead the development of its APITOX program.

Apimeds Pharmaceuticals US, Inc. announced a revised effective date for its previously approved 1-for-10 reverse stock split, now set for July 24, 2026.

Apimeds Pharmaceuticals US, Inc. announced the appointment of Sungjoon Chae as Co-Chief Executive Officer, effective May 4, 2026.

Apimeds Pharmaceuticals US, Inc. has entered into a settlement and mutual release agreement to resolve outstanding disputes, restructure its operations, and establish new governance for its subsidiaries.

Apimeds Pharmaceuticals has received a notice of non-compliance from the NYSE American due to the delayed filing of its 2025 Annual Report.

Apimeds Pharmaceuticals US, Inc. announced a delay in filing its 2025 Annual Report on Form 10-K, citing ongoing audit procedures.

Apimeds Pharmaceuticals US, Inc. clarifies that actions by majority stockholders to remove directors and officers are null and void due to contractual violations.

Apimeds Pharmaceuticals US, Inc. announced a material breach of its merger agreement by Inscobee Inc., which attempted a hostile takeover of its Board of Directors.

Apimeds Pharmaceuticals US, Inc. announces a complete board and executive management overhaul by majority stockholders, new business expansion into Korean markets, and a delayed reverse stock split, all while facing a challenge from MindWave Innovations Inc. regarding a previously reported merger.

Apimeds Pharmaceuticals US, Inc. will effect a 1-for-10 reverse stock split of its common stock, effective March 26, 2026, to be traded on a split-adjusted basis on the NYSE American LLC.

Apimeds Pharmaceuticals US, Inc. announced the removal of Erik Emerson from its board of directors, effective December 30, 2025, by stockholder vote.

Apimeds Pharmaceuticals US, Inc. announced the resignations of Dr. Vin Menon and Amir A. Dossal from its Board of Directors, effective December 5, 2025.

Apimeds Pharmaceuticals US, Inc. filed an amendment to correct clerical errors in its Merger Agreement and Certificate of Designation, and modified a Securities Purchase Agreement.

Apimeds Pharmaceuticals US, Inc. merged with MindWave Innovations Inc, combining biotech and AI-driven digital asset treasury, supported by a concurrent PIPE of up to $100 million.

Apimeds amended its CEO contract to raise base pay to $500,000 and provide 24 months of severance plus immediate vesting of unvested equity if terminated without cause, effective November 13, 2025.

Apimeds Pharmaceuticals US, Inc. announced an amendment to its bylaws, enabling shareholders to take action by written consent without a formal meeting.

Apimeds Pharmaceuticals US, Inc. announced the appointment of Dr. Susan Kramer as Senior Vice President of Development and Brian Peters as Head of its proprietary AI division, strengthening its executive leadership team.

Apimeds Pharmaceuticals US, Inc. has announced the appointment of Erick J. Frim, a financial executive with over 40 years of experience, as its new Chief Financial Officer, replacing Mark Corrao.

Apimeds Pharmaceuticals US, Inc. has amended the terms of three outstanding promissory notes, extending their maturity date to May 19, 2026.

Apimeds Pharmaceuticals US, Inc. successfully closed its initial public offering, raising $13.5 million to advance its clinical-stage biopharmaceutical development.

Apimeds Pharmaceuticals US, Inc. updated its bylaws on April 11, 2025, impacting stockholder proposal procedures, meeting requirements, director roles, and litigation forums.